Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 26

1.

Cangrelor: A Review in Percutaneous Coronary Intervention.

Keating GM.

Drugs. 2015 Aug;75(12):1425-34. doi: 10.1007/s40265-015-0445-3. Review.

PMID:
26201463
2.

Comparative efficacy and safety of anticoagulant strategies for acute coronary syndromes. Comprehensive network meta-analysis of 42 randomised trials involving 117,353 patients.

Navarese EP, Andreotti F, Kołodziejczak M, Schulze V, Wolff G, Dias S, Claessen B, Brouwer M, Tarantini G, Iliceto S, Brockmeyer M, Kowalewski M, Lin Y, Eikelboom J, Musumeci G, Lee L, Lip GY, Valgimigli M, Berti S, Kelm M.

Thromb Haemost. 2015 Nov;114(5):933-44. doi: 10.1160/TH14-12-1066. Epub 2015 Jul 16.

PMID:
26177601
3.

Pre-treatment with dual antiplatelet therapy in patients with non-ST-segment elevation acute coronary syndromes undergoing percutaneous coronary intervention.

Yudi MB, Eccleston D, Andrianopoulos N, Farouque O, Duffy SJ, Brennan A, Reid C, Clark DJ, Ajani AE; Melbourne Interventional Group..

Intern Med J. 2015 Oct;45(10):1032-7. doi: 10.1111/imj.12818.

PMID:
26013065
4.

Conflicting results between randomized trials and observational studies on the impact of proton pump inhibitors on cardiovascular events when coadministered with dual antiplatelet therapy: systematic review.

Melloni C, Washam JB, Jones WS, Halim SA, Hasselblad V, Mayer SB, Heidenfelder BL, Dolor RJ.

Circ Cardiovasc Qual Outcomes. 2015 Jan;8(1):47-55. doi: 10.1161/CIRCOUTCOMES.114.001177. Epub 2015 Jan 13. Review. Erratum in: Circ Cardiovasc Qual Outcomes. 2016 Sep;9(5):614.

5.

Reduction in overall occurrences of ischemic events with vorapaxar: results from TRACER.

White HD, Huang Z, Tricoci P, Van de Werf F, Wallentin L, Lokhnygina Y, Moliterno DJ, Aylward PE, Mahaffey KW, Armstrong PW.

J Am Heart Assoc. 2014 Jul 10;3(4). pii: e001032. doi: 10.1161/JAHA.114.001032.

6.
7.

Duration of eptifibatide infusion after percutaneous coronary intervention and outcomes among high-risk patients with non-ST-segment elevation acute coronary syndrome: insights from EARLY ACS.

Hess CN, Schulte PJ, Newby LK, Steg PG, Dalby AJ, Schweiger MJ, Lewis BS, Armstrong PW, Califf RM, van de Werf F, Harrington RA.

Eur Heart J Acute Cardiovasc Care. 2013 Sep;2(3):246-55. doi: 10.1177/2048872612474922.

8.

Updates in antiplatelet agents used in cardiovascular diseases.

Cheng JW.

J Cardiovasc Pharmacol Ther. 2013 Nov;18(6):514-24. doi: 10.1177/1074248413499971. Review.

PMID:
24213473
9.

Bivalirudin versus unfractionated heparin during percutaneous coronary intervention in patients with non-ST-segment elevation acute coronary syndrome initially treated with fondaparinux: results from an international, multicenter, randomized pilot study (SWITCH III).

Waksman R, Bertrand O, Driesman M, Gruberg L, Rossi J, Mehta S, Swymelar S, Dvir D, Xue Z, Torguson R.

J Interv Cardiol. 2013 Apr;26(2):107-13. doi: 10.1111/joic.12005. Epub 2012 Dec 13.

PMID:
23240743
10.
11.

Early versus delayed percutaneous coronary intervention for patients with non-ST segment elevation acute coronary syndrome: a meta-analysis of randomized controlled clinical trials.

Rajpurohit N, Garg N, Garg R, Choudhary A, Fresen J, Boren S, Dellsperger KC, Webel R, Aggarwal K, Alpert MA.

Catheter Cardiovasc Interv. 2013 Feb;81(2):223-31. doi: 10.1002/ccd.24439. Epub 2012 May 24. Review. Erratum in: Catheter Cardiovasc Interv. 2013 Jun 1;81(7):1255.

PMID:
22488783
12.

Safety and efficacy of adjusted-dose eptifibatide in patients with acute coronary syndromes and reduced renal function.

Melloni C, James SK, White JA, Giugliano RP, Harrington RA, Huber K, Tricoci P, Armstrong PW, Van de Werf F, Montalescot G, Califf RM, Newby LK.

Am Heart J. 2011 Nov;162(5):884-892.e1. doi: 10.1016/j.ahj.2011.08.020.

PMID:
22093205
13.

Platelet glycoprotein IIb/IIIa blockers during percutaneous coronary intervention and as the initial medical treatment of non-ST segment elevation acute coronary syndromes.

Bosch X, Marrugat J, Sanchis J.

Cochrane Database Syst Rev. 2010 Sep 8;(9):CD002130. doi: 10.1002/14651858.CD002130.pub2. Review. Update in: Cochrane Database Syst Rev. 2013;10:CD002130.

PMID:
20824831
14.

A risk score to predict bleeding in patients with acute coronary syndromes.

Mehran R, Pocock SJ, Nikolsky E, Clayton T, Dangas GD, Kirtane AJ, Parise H, Fahy M, Manoukian SV, Feit F, Ohman ME, Witzenbichler B, Guagliumi G, Lansky AJ, Stone GW.

J Am Coll Cardiol. 2010 Jun 8;55(23):2556-66. doi: 10.1016/j.jacc.2009.09.076.

15.

The PACIFIC (Prevention of AtherothrombotiC Incidents Following Ischemic Coronary attack) Registry: Rationale and design of a 2-year study in patients initially hospitalised with acute coronary syndrome in Japan.

Miyauchi K, Morino Y, Tsukahara K, Origasa H, Daida H; PACIFIC steering committee members..

Cardiovasc Drugs Ther. 2010 Feb;24(1):77-83. doi: 10.1007/s10557-010-6223-2.

PMID:
20352313
16.

Relationship between baseline haemoglobin and major bleeding complications in acute coronary syndromes.

Bassand JP, Afzal R, Eikelboom J, Wallentin L, Peters R, Budaj A, Fox KA, Joyner CD, Chrolavicius S, Granger CB, Mehta S, Yusuf S; OASIS 5 and OASIS 6 Investigators..

Eur Heart J. 2010 Jan;31(1):50-8. doi: 10.1093/eurheartj/ehp401. Epub 2009 Oct 12.

PMID:
19825809
17.

Obesity in patients with non-ST-segment elevation acute coronary syndromes: results from the SYNERGY trial.

Mahaffey KW, Tonev ST, Spinler SA, Levine GN, Gallo R, Ducas J, Goodman SG, Antman EM, Becker RC, Langer A, White HD, Aylward PE, Col JJ, Ferguson JJ, Califf RM; SYNERGY Trial Investigators..

Int J Cardiol. 2010 Mar 4;139(2):123-33. doi: 10.1016/j.ijcard.2008.10.008. Epub 2008 Nov 14.

PMID:
19012977
18.

Outcomes in elderly patients with acute coronary syndromes randomized to enoxaparin vs. unfractionated heparin: results from the SYNERGY trial.

Lopes RD, Alexander KP, Marcucci G, White HD, Spinler S, Col J, Aylward PE, Califf RM, Mahaffey KW.

Eur Heart J. 2008 Aug;29(15):1827-33. doi: 10.1093/eurheartj/ehn236. Epub 2008 Jun 2.

PMID:
18519426
19.

Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidogrel, in patients with non-ST-segment elevation acute coronary syndrome: primary results of the DISPERSE-2 trial.

Cannon CP, Husted S, Harrington RA, Scirica BM, Emanuelsson H, Peters G, Storey RF; DISPERSE-2 Investigators..

J Am Coll Cardiol. 2007 Nov 6;50(19):1844-51. Epub 2007 Oct 23. Erratum in: J Am Coll Cardiol. 2007 Nov 27;50(22):2196.

20.

Efficacy and safety of enoxaparin compared with unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention in the Superior Yield of the New Strategy of Enoxaparin, Revascularization and Glycoprotein IIb/IIIa Inhibitors (SYNERGY) trial.

White HD, Kleiman NS, Mahaffey KW, Lokhnygina Y, Pieper KS, Chiswell K, Cohen M, Harrington RA, Chew DP, Petersen JL, Berdan LG, Aylward PE, Nessel CC, Ferguson JJ 3rd, Califf RM.

Am Heart J. 2006 Dec;152(6):1042-50. Erratum in: Am Heart J. 2007 Feb;153(2):327.

PMID:
17161049

Supplemental Content

Loading ...
Support Center